Základ účasti na Studii Sample Clauses

Základ účasti na Studii. Účast Poskytovatele nebo Hlavního zkoušejícího na Studii není založena na žádném předchozím ani budoucím obchodním vztahu mezi společností XXX a Hlavním zkoušejícím nebo Poskytovatelem. Není xxx xxxxxx na žádná obchodní či xxxx rozhodnutí Hlavního zkoušejícího nebo Poskytovatele ohledně společnosti XXX nebo jejích přípravků. 2.2 Sdělování a oznamování informací C RO nebo společností XXX. V zájmu transparentnosti vztahů se zkoušejícími a pracovišti, kde xx xxxxxx prováděna, nebo za účelem zajištění souladu s platnými místními právními předpisy je společnost XXX oprávněna zveřejnit informace o podpoře, kterou poskytuje podle této Smlouvy. V takovém sdělení je společnosti XXX oprávněna uvést identifikační údaje Poskytovatele i totožnost Hlavního zkoušejícího, ale bude jasně rozlišovat mezi platbami nebo jiným plněním poskytovaným poskytovateli xx xxxxxx jedné a platbami a jiným plněním poskytovaným fyzickým osobám xx xxxxxx druhé. 2.3
AutoNDA by SimpleDocs

Related to Základ účasti na Studii

  • meminta nasihat daripada Pihak Xxxxxx dalam semua perkara berkenaan dengan jualan lelongan, termasuk Syarat-syarat Jualan (iii) membuat carian Hakmilik Xxxxx xxxxxx rasmi di Pejabat Tanah xxx/atau xxxx-xxxx Pihak-pihak Berkuasa yang berkenaan xxx (iv) membuat pertanyaan dengan Pihak Berkuasa yang berkenaan samada jualan ini terbuka kepada semua bangsa atau kaum Bumiputra Warganegara Malaysia sahaja atau melayu sahaja xxx juga mengenai persetujuan untuk jualan ini sebelum jualan lelong.Penawar yang berjaya (“Pembeli”) dikehendaki dengan segera memohon xxx mendapatkan kebenaran pindahmilik (jika ada) daripada Pihak Pemaju xxx/atau Pihak Tuanpunya xxx/atau Pihak Berkuasa Negeri atau badan-badan berkenaan (v) memeriksa xxx memastikan samada jualan ini dikenakan cukai. BUTIR-BUTIR HARTANAH : HAKMILIK : Hakmilik strata bagi hartanah ini masih belum dikeluarkan oleh pihak berkuasa. NO. HAKMILIK INDUK / NO. LOT : Geran 203771, Lot 106 Seksyen 3 PEKAN/DAERAH/NEGERI : Pekan Batu Tiga / Petaling / Selangor Darul Ehsan PEGANGAN : Selama-lamanya KELUASAN LANTAI : 93.65 meter persegi (1,008 kaki persegi) PEMAJU : Shanghai Realty (M) Sdn Bhd (350799-U) XXXXXXXX XXX : Xxxxxxxx Xxxxx Bin Xxxxxx BEBANAN : Diserahhak kepada RHB Islamic Bank Berhad (200501003283/680329-V) LOKASI XXX PERIHAL HARTANAH Hartanah tersebut terletak di Pangsapuri Indahria, Xx. 0, Xxxxx Xxxx Xxxx-Xxxxxx Xxxxx, Xxxxx Xxxxxxx, Xxxxxxx 00, 00000 Xxxx Xxxx, Xxxxxxxx Xxxxx Xxxxx. Hartanah tersebut adalah sebuah unit pangsapuri dikenali sebagai Xxxxx Pemaju No. P5-2-11, Tingkat No. 2, Bangunan No. P5, berserta dengan Xxxxx Aksesori No. GRD-07, Pangsapuri Indahria xxx mempunyai alamat surat-menyurat di Unit No. P5-02-11, Pangsapuri Indahria, Xx. 0, Xxxxx Xxxx Xxxx-Xxxxxx Xxxxx, Xxxxx Xxxxxxx, Xxxxxxx 00, 00000 Xxxx Xxxx, Xxxxxxxx Xxxxx Xxxxx. HARGA RIZAB: Harta ini dijual “keadaan seperti mana sediada” dengan harga rizab sebanyak RM 270,000.00 (RINGGIT MALAYSIA: DUA RATUS XXX TUJUH PULUH RIBU SAHAJA) xxx tertakluk kepada syarat-syarat Jualan xxx melalui penyerahan hakkan dari Pemegang Serahak, tertakluk kepada kelulusan di perolehi oleh pihak Pembeli daripada pihak berkuasa, jika ada, termasuk semua terma, syarat xxx perjanjian yang dikenakan xxx mungkin dikenakan oleh Pihak Berkuasa yang berkenaan. Pembeli bertanggungjawab sepenuhnya untuk memperolehi xxx mematuhi syarat- syarat berkenaan daripada Pihak Berkuasa yang berkenaan, jika ada xxx semua xxx xxx perbelanjaan ditanggung xxx dibayar oleh Xxxxx Xxxxxxx.Pembeli atas talian (online) juga tertakluk kepada terma-terma xxx syarat-syarat terkandung dalam xxx.xxxxxxxxxxxxxxxx.xxx Pembeli yang berminat adalah dikehendaki mendeposit kepada Pelelong 10% daripada harga rizab dalam bentuk Bank Draf atau Cashier’s Order di atas nama RHB Islamic Bank Berhad sebelum lelongan awam xxx xxxx xxxx xxxxxx bersama-sama dengan segala cukai jualan xxx perkhidmatan (SST) xxx/atau cukai yang menggantikan SST hendaklah dibayar dalam tempoh sembilan puluh (90) hari dari tarikh lelongan kepada RHB Islamic Bank Berhad melalui XXXXXX. Butir-butir pembayaran melalui XXXXXX, xxxx berhubung dengan Tetuan T. Rajagopalu & Co. Untuk maklumat lanjut, xxxx berhubung dengan TETUAN T. RAJAGOPALU & CO, Solicitors for Assignee herein whose address is at Xxxxx 0-0, Xxxxxxxx Xxxx Xxxxxx Xxxxx Xxxxx, 00000 Xxxxxxxx Xxxxxx Xxxxxxxx. Tel: 00-0000000 / Fax: 00-0000000 [Ruj: RG/RHB/0339/2023/SYAFIQAH(yusof)], peguamcara bagi pihak pemegang xxxxx xxx atau pelelong yang tersebut dibawah. RAJAN AUCTIONEERS SDN. BHD. X. XXXXX Xx.00X,Xxxxxxx Xxxx,Xxxxx Xxxx Xxxxxx, ( Xxxxxxxx Berlesen ) 41000 Klang, Selangor Darul Ehsan. H/P: 000-0000000 Tel: 00-00000000 / Fax : 00-00000000 H/P: 012-2738109 Ruj Kami: RA/RHBI/TRC/NS/4220-24(fz) CONDITIONS OF SALE

  • MSEA SEIU shall have exclusive rights to payroll deduction of membership dues, service fees, and premiums for current MSEA-SEIU spon- sored insurance programs. Deductions for other programs may be mutually agreed to by the parties.

  • Curriculum Vitae (a) The Chief Librarian shall maintain a curriculum vita for each Librarian. It is the Librarian’s responsibility to ensure that the curriculum vita on file is kept current. Members shall prepare their curriculum vita with the advice and assistance of their Chief Librarian. Members may revise their curriculum vita at any time.

  • BUY AMERICA ACT (National School Lunch Program and Breakfast Program With respect to products purchased by Customers for use in the National School Lunch Program and/or National School Breakfast Program, Contractor shall comply with all federal procurement laws and regulations with respect to such programs, including the Buy American provisions set forth in 7 C.F.R. Part 210.21(d), to the extent applicable. Contractor agrees to provide all certifications required by Customer regarding such programs. In the event Contractor or Contractor’s supplier(s) are unable or unwilling to certify compliance with the Buy American Provision, or the applicability of an exception to the Buy American provision, H-GAC Customers may decide not to purchase from Contractor. Additionally, H-GAC Customers may require country of origin on all products and invoices submitted for payment by Contractor, and Contractor agrees to comply with any such requirement.

  • Technology Research Analyst Job# 1810 General Characteristics Maintains a strong understanding of the enterprise’s IT systems and architectures. Assists in the analysis of the requirements for the enterprise and applying emerging technologies to support long-term business objectives. Responsible for researching, collecting, and disseminating information on emerging technologies and key learnings throughout the enterprise. Researches and recommends changes to foundation architecture. Supports research projects to identify and evaluate emerging technologies. Interfaces with users and staff to evaluate possible implementation of the new technology in the enterprise, consistent with the goal of improving existing systems and technologies and in meeting the needs of the business. Analyzes and researches process of deployment and assists in this process.

  • Přetrvávající platnost Tento odstavec 1.3 “Zdravotní záznamy a Studijní data a údaje” zůstane závazný i v případě zániku platnosti či vypršení platnosti této Smlouvy.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Development Plans 4.3.1 For each Licensed Indication and corresponding Licensed Product in the Field, Licensee will prepare and deliver to Licensor a development plan and budget (each a “Development Plan”). The initial Development Plans for each Licensed Indication will be delivered within […***…] after the Grant Date for such Licensed Indication.

Time is Money Join Law Insider Premium to draft better contracts faster.